Title

Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Randomized Prospective Study of T3 on the Incidence of Post-Operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    liothyronine ...
  • Study Participants

    280
The purpose of this project is to see whether treatment with a thyroid hormone, called triiodothyronine or T3, following open heart surgery reduces the risk of developing atrial fibrillation.
Study Started
Feb 28
2006
Primary Completion
Aug 31
2006
Study Completion
May 31
2008
Last Update
May 20
2008
Estimate

Drug Triiodothyronine

0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.

Drug triiodothyronine

IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.

Criteria

Inclusion Criteria:

Patients requiring CABG or valve repair/replacement surgery.
Patient must be able to provide informed consent.

Exclusion Criteria:

Patients less than 18 or over 85 years of age.
Patients less than 50kg or greater than 120kg.
Patients currently with endocrine disorders, excluding diabetes.
Patients currently with thyroid dysfunction (e.g., hyper- hyperthyroidism, goiter, Grave's disease), myxedema, or myxedema coma, even if treated.
Patients currently receiving thyroid replacement therapy.
Patients currently receiving Ketamine, levarterenol or dietary (non-food) iodine supplementation.
Patients who have received any investigational drugs within the previous one month or five half-lives of the drug.
Patients who are pregnant. Pregnancy testing will be done for women of child-bearing potential.
Patients currently in atrial fibrillation.
No Results Posted